|
Market Closed -
Nasdaq
16:00:00 2026-09-21 EDT
|
5-day change | 1st Jan Change | ||
| 39.66 USD | -1.95% |
|
-9.08% | +30.72% |
| 08-05 | Rapport Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 07-28 | William Blair Initiates Rapport Therapeutics at Outperform | MT |
Company Valuation: Rapport Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 648.9 | 1,446 | 1,941 | - | - |
| Change | - | 122.86% | 34.21% | - | - |
| Enterprise Value (EV) 1 | 343.6 | 955.5 | 1,612 | 1,464 | 1,941 |
| Change | - | 178.1% | 68.67% | -9.16% | 32.56% |
| P/E | -4.69x | -10.6x | -9.79x | -8.09x | -7.32x |
| PBR | - | 2.99x | - | - | - |
| PEG | -0.1x | 0.4x | -0.2x | -0.4x | -0.7x |
| Capitalization / Revenue | - | - | 97x | - | - |
| EV / Revenue | - | - | 80.6x | - | - |
| EV / EBITDA | -4.18x | -7.7x | -7.87x | -5.92x | -7.07x |
| EV / EBIT | -4.14x | -7.64x | -7.75x | -5.55x | -6.34x |
| EV / FCF | -5.11x | -10.8x | -8.47x | -6.79x | -8.93x |
| FCF Yield | -19.6% | -9.22% | -11.8% | -14.7% | -11.2% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -3.78 | -2.86 | -4.05 | -4.902 | -5.42 |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | - | - | 20 | - | - |
| EBITDA 1 | -82.22 | -124.1 | -204.9 | -247.2 | -274.6 |
| EBIT 1 | -83.06 | -125.1 | -208 | -263.8 | -306.3 |
| Net income 1 | -78.31 | -111.5 | -194.1 | -252.4 | -297 |
| Net Debt 1 | -305.3 | -490.5 | -329.1 | -476.7 | - |
| Reference price 2 | 17.74 | 30.34 | 39.66 | 39.66 | 39.66 |
| Nbr of stocks (in thousands) | 36,576 | 47,661 | 47,978 | - | - |
| Announcement Date | 3/11/25 | 3/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.99x | 80.58x | -7.87x | - | 1.94B | |
| 31.88x | 5.74x | 17.19x | 1.02% | 46.28B | |
| 34.31x | 3.31x | 14.29x | -.--% | 43.85B | |
| -19.53x | 224.63x | -20.86x | -.--% | 40.93B | |
| 45.96x | 5.31x | 29.04x | -.--% | 39.89B | |
| 27.09x | 7.81x | 19.95x | 0.42% | 29.5B | |
| 34.82x | 5.71x | 25.95x | -.--% | 17.09B | |
| 25.48x | 2.19x | 9.51x | 1.05% | 15.22B | |
| -55.89x | 9.19x | 224.28x | -.--% | 14.05B | |
| Average | 12.68x | 38.27x | 34.61x | 0.31% | 27.64B | |
| Weighted average by Cap. | 20.07x | 42.06x | 24.28x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RAPP Stock
- Valuation Rapport Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
